Biosign Closes Oversubscribed Private Placement

/THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR
    FOR DISSEMINATION IN THE UNITED STATES/

TORONTO, Oct. 9 /CNW/ - Biosign Technologies Inc. (CNSX: BIO) (the "Company" or "Biosign") reports that its previously announced $1 million non-brokered private placement was oversubscribed, allocated, and is closed effective today.

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit http://www.biosign.com.

The CNSX has neither approved nor disapproved the contents of this press release.

%SEDAR: 00014068E

For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: [phone] ext. 234, Email: [e-mail]